JP2012509066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509066A5 JP2012509066A5 JP2011536582A JP2011536582A JP2012509066A5 JP 2012509066 A5 JP2012509066 A5 JP 2012509066A5 JP 2011536582 A JP2011536582 A JP 2011536582A JP 2011536582 A JP2011536582 A JP 2011536582A JP 2012509066 A5 JP2012509066 A5 JP 2012509066A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- independently
- seq
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 108091034117 Oligonucleotide Proteins 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 125000000524 functional group Chemical group 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 10
- 230000000890 antigenic effect Effects 0.000 claims 9
- 239000012867 bioactive agent Substances 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 9
- 230000001737 promoting effect Effects 0.000 claims 9
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 210000001163 endosome Anatomy 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- GUCPYIYFQVTFSI-UHFFFAOYSA-N 4-methoxybenzamide Chemical compound COC1=CC=C(C(N)=O)C=C1 GUCPYIYFQVTFSI-UHFFFAOYSA-N 0.000 claims 2
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims 2
- 102000013918 Apolipoproteins E Human genes 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 108700011259 MicroRNAs Proteins 0.000 claims 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 claims 2
- 230000001588 bifunctional effect Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229960000304 folic acid Drugs 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- -1 leaving group Chemical group 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims 2
- 102100036537 von Willebrand factor Human genes 0.000 claims 2
- 229960001134 von willebrand factor Drugs 0.000 claims 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 claims 1
- 0 C*C(CCCCCN(*)[C@](C=CC=O)O)=O Chemical compound C*C(CCCCCN(*)[C@](C=CC=O)O)=O 0.000 description 4
- MFSLTRMRYVDMOI-UHFFFAOYSA-N CC(C)NCCCCCN(C(CC1C)=O)C1=O Chemical compound CC(C)NCCCCCN(C(CC1C)=O)C1=O MFSLTRMRYVDMOI-UHFFFAOYSA-N 0.000 description 1
- KAJJUFUPJGVIFJ-UHFFFAOYSA-N CC(CC(N1)=O)C1=O Chemical compound CC(CC(N1)=O)C1=O KAJJUFUPJGVIFJ-UHFFFAOYSA-N 0.000 description 1
- AVBXNXQAYPNGJK-UHFFFAOYSA-N CCC(C)C(C)=N Chemical compound CCC(C)C(C)=N AVBXNXQAYPNGJK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11535008P | 2008-11-17 | 2008-11-17 | |
| US11532608P | 2008-11-17 | 2008-11-17 | |
| US61/115,350 | 2008-11-17 | ||
| US61/115,326 | 2008-11-17 | ||
| PCT/US2009/064711 WO2010057154A1 (en) | 2008-11-17 | 2009-11-17 | Releasable conjugates for nucleic acids delivery systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509066A JP2012509066A (ja) | 2012-04-19 |
| JP2012509066A5 true JP2012509066A5 (enExample) | 2013-01-10 |
Family
ID=42170405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536582A Pending JP2012509066A (ja) | 2008-11-17 | 2009-11-17 | 核酸送達系のための放出可能接合体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110230420A1 (enExample) |
| EP (1) | EP2362729A1 (enExample) |
| JP (1) | JP2012509066A (enExample) |
| CN (1) | CN102231951A (enExample) |
| CA (1) | CA2742842A1 (enExample) |
| TW (1) | TW201029668A (enExample) |
| WO (1) | WO2010057154A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10766928B2 (en) | 2012-10-05 | 2020-09-08 | The University Of Kansas | Targeted conformationally-constrained kinked endosomal disrupting peptides |
| US9701715B2 (en) * | 2012-10-05 | 2017-07-11 | The University Of Kansas | Conformationally-constrained kinked endosomal-disrupting peptides |
| US9365599B2 (en) | 2012-10-26 | 2016-06-14 | Korea Atomic Energy Research Institute | N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient |
| WO2017024182A1 (en) | 2015-08-04 | 2017-02-09 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
| CN106466484B (zh) * | 2015-08-11 | 2021-05-04 | 同宜医药（苏州）有限公司 | 一种具有细胞内吞介导功能的多靶向配体-药物偶联体 |
| MX381031B (es) * | 2015-08-11 | 2025-03-12 | Coherent Biopharma | Ltd | Conjugados fármaco-multiligando y usos de los mismos. |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| WO2018053201A1 (en) | 2016-09-14 | 2018-03-22 | Duke University | Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs |
| EP3515928B1 (en) | 2016-09-23 | 2026-01-28 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| EP3658168A4 (en) | 2017-06-30 | 2021-07-14 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS |
| CN107629118A (zh) * | 2017-10-31 | 2018-01-26 | 天津大学 | 基于组氨酸的靶向性穿膜肽载体及用途 |
| WO2019147954A1 (en) | 2018-01-26 | 2019-08-01 | Duke University | Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| US11649275B2 (en) | 2018-08-02 | 2023-05-16 | Duke University | Dual agonist fusion proteins |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| US20250297258A1 (en) * | 2021-07-07 | 2025-09-25 | Ractigen Therapeutics | Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| WO2002085908A1 (en) * | 2001-04-24 | 2002-10-31 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| SI2264172T1 (sl) * | 2002-04-05 | 2017-12-29 | Roche Innovation Center Copenhagen A/S | Oligomerne spojine za modulacijo izražanja HIF-1alfa |
| US7713738B2 (en) * | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
| EP2251039A3 (en) * | 2003-05-30 | 2010-12-08 | Nippon Shinyaku Co., Ltd. | Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same |
| AU2005207026A1 (en) * | 2004-01-22 | 2005-08-04 | Immunomedics, Inc. | Folate conjugates and complexes |
| GB0415263D0 (en) * | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
| US7772201B2 (en) * | 2004-11-17 | 2010-08-10 | “University of Maryland, Baltimore” | Highly branched HK peptides as effective carriers of siRNA |
| JP2008527993A (ja) * | 2005-01-24 | 2008-07-31 | アヴァリス・アクチエボラーグ | 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体 |
| EP2073820A4 (en) * | 2006-09-15 | 2014-07-16 | Belrose Pharma Inc | TARGETED POLYMER PRODRUGS WITH MULTIFUNCTIONAL CONNECTORS |
| MX2009002856A (es) * | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Conjugados polimericos que contienen porciones cargadas positivamente. |
| LT2494993T (lt) * | 2007-05-04 | 2018-12-27 | Marina Biotech, Inc. | Aminorūgščių lipidai ir jų panaudojimas |
-
2009
- 2009-11-17 US US13/129,705 patent/US20110230420A1/en not_active Abandoned
- 2009-11-17 JP JP2011536582A patent/JP2012509066A/ja active Pending
- 2009-11-17 CA CA2742842A patent/CA2742842A1/en not_active Abandoned
- 2009-11-17 TW TW098138944A patent/TW201029668A/zh unknown
- 2009-11-17 WO PCT/US2009/064711 patent/WO2010057154A1/en not_active Ceased
- 2009-11-17 CN CN200980145913XA patent/CN102231951A/zh active Pending
- 2009-11-17 EP EP09826949A patent/EP2362729A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2427472T3 (en) | Lipophilic polynukleotidkonjugater | |
| KR102335801B1 (ko) | 안티센스 핵산 | |
| EP2796150B1 (en) | Novel oligonucleotide conjugates and use thereof | |
| JP2012509273A5 (enExample) | ||
| US9745421B2 (en) | Dendronized polymers for nucleic acid delivery | |
| US20070218122A1 (en) | siRNA silencing of influenza virus gene expression | |
| JP2012509366A5 (enExample) | ||
| JP2023158214A (ja) | Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法 | |
| KR20090055623A (ko) | 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커 | |
| JP2015523854A5 (enExample) | ||
| JP2011516094A (ja) | 干渉ｒｎａを用いたｃｓｎ５遺伝子発現のサイレンシング方法 | |
| CA3033577A1 (en) | Novel lipids and compositions for the delivery of therapeutics | |
| CN114380724A (zh) | 用于递送核酸的阳离子脂质化合物和组合物及用途 | |
| JP2023002587A (ja) | アンフィレグリン遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| KR20220122673A (ko) | 엑손 50의 스키핑을 유도하는 안티센스 핵산 | |
| Fakhoury et al. | Antisense precision polymer micelles require less poly (ethylenimine) for efficient gene knockdown | |
| KR101715228B1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA 를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
| JP2023533124A (ja) | 二本鎖オリゴヌクレオチド及びこれを含むコロナウイルス感染症－１９（ｃｏｖｉｄ－１９）治療用組成物 | |
| US20250242036A1 (en) | Trans-membrane delivery systems and uses thereof | |
| Anada et al. | Linear double-stranded DNA that mimics an infective tail of virus genome to enhance transfection | |
| US20260092085A1 (en) | Synthetic triplex peptide nucleic acid-based inhibitors for cancer therapy | |
| JP7709164B2 (ja) | 核酸送達促進剤 | |
| CN121419780A (zh) | 用于抑制甲型流感病毒基因表达的RNAi试剂、其组合物和使用方法 | |
| Yoon et al. | γ-Amino Carboxylic Acid Modification Enhances the Efficacy of PNAs Targeting miR-221-3p in A549 Cells | |
| WO2023171804A1 (ja) | 抗ウイルスアンチセンスオリゴマー |